A useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors

Kidney International

Volumn 86, Issue 6, 2014, Pages 1130-1139

  Chapal, Marion ^a,b   Le Borgne, Florent ^c   Legendre, Christophe ^d,e   Kreis, Henri ^d,e   Mourad, Georges ^f   Garrigue, Valérie ^f   Morelon, Emmanuel ^g   Buron, Fanny ^g   Rostaing, Lionel ^h,i   Kamar, Nassim ^h,i   Kessler, Michèle ^j   Ladrière, Marc ^j   Soulillou, Jean Paul ^a,b   Launay, Katy ^a,c   Daguin, Pascal ^a   Offredo, Lucile ^c   Giral, Magali ^a,b   Foucher, Yohann ^a,c  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c Universite de Nantes   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f LAPEYRONIE HOSPITAL   (France)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h CHU RANGUEIL   (France)

ⁱ UNIVERSITÉ PAUL SABATIER   (France)

^j CHU NANCY BRABOIS   (France)

more..

Author keywords

Delayed graft function; Kidney transplantation; Risk factors; Statistics; Transplant outcomes

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ADULT; ARTICLE; BODY MASS; CADAVER DONOR; CALIBRATION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL PRACTICE; COHORT ANALYSIS; COLD ISCHEMIA; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; DIABETES MELLITUS; DIALYSIS; DYSLIPIDEMIA; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MULTICENTER STUDY; NEOPLASM; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT INDICATION; ADOLESCENT; ADVERSE EFFECTS; AGE; AGED; AREA UNDER THE CURVE; BLOOD; CADAVER; CHILD; CLINICAL TRIAL; DECISION SUPPORT SYSTEM; DONOR; INFANT; MIDDLE AGED; MOBILE APPLICATION; PRESCHOOL CHILD; RISK FACTOR; SMARTPHONE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTILYMPHOCYTE SERUM; AREA UNDER CURVE; BODY MASS INDEX; CADAVER; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLD ISCHEMIA; CREATININE; DECISION SUPPORT TECHNIQUES; DELAYED GRAFT FUNCTION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; INFANT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MOBILE APPLICATIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SMARTPHONE; TISSUE DONORS; YOUNG ADULT;

EID: 84926179759     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.188     Document Type: Article

References (49)

1. Miller J, Mendez R, Pirsch JD et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69: 875-880.
2. Yarlagadda SG, Coca SG, Garg AX et al. Marked variation in the definition and diagnosis of delayed graft function: A systematic review. Nephrol Dial Transplant 2008; 23: 2995-3003.
3. Perico N, Cattaneo D, Sayegh MH et al. Delayed graft function in kidney transplantation. Lancet 2004; 364: 1814-1827.
4. Tapiawala SN, Tinckam KJ, Cardella CJ et al. Delayed graft function and the risk for death with a functioning graft. J Am Soc Nephrol 2010; 21: 153-161.
5. Yarlagadda SG, Coca SG, Formica RN Jr. et al. Association between delayed graft function and allograft and patient survival: A systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24: 1039-1047.
6. Giral M, Bertola JP, Foucher Y et al. Effect of brain-dead donor resuscitation on delayed graft function: results of a monocentric analysis. Transplantation 2007; 83: 1174-1181.
7. Schnuelle P, Gottmann U, Hoeger S et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: A randomized controlled trial. JAMA 2009; 302: 1067-1075.
8. Arumugam TV, Shiels IA, Strachan AJ et al. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 2003; 63: 134-142.
9. Kelly KJ, Williams WW Jr., Colvin RB et al. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 1994; 91: 812-816.
10. Knight SF, Kundu K, Joseph G et al. Folate receptor-targeted antioxidant therapy ameliorates renal ischemia-reperfusion injury. J Am Soc Nephrol 2012; 23: 793-800.
11. Thurman JM, Royer PA, Ljubanovic D et al. Treatment with an inhibitory monoclonal antibody to mouse factor B protects mice from induction of apoptosis and renal ischemia/reperfusion injury. J Am Soc Nephrol 2006; 17: 707-715.
12. Kaden J, May G, Strobelt V et al. Intraoperative T-cell depletion prior to completion of anastomoses by high-dose single ATG bolus as a new approach to improve long-term results after kidney transplantation. Transplant Proc 1997; 29: 344-347.
13. Kyllonen LE, Eklund BH, Pesonen EJ et al. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation 2007; 84: 75-82.
14. Turunen AJ, Lindgren L, Salmela KT et al. Association of graft neutrophil sequestration with delayed graft function in clinical renal transplantation. Transplantation 2004; 77: 1821-1826.
15. Haririan A, Morawski K, Sillix DH et al. Induction therapy with basiliximab versus Thymoglobulin in African-American kidney transplant recipients. Transplantation 2005; 79: 716-721.
16. Mourad G, Rostaing L, Legendre C et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584-590.
17. Sollinger H, Kaplan B, Pescovitz MD et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72: 1915-1919.
18. Ulrich F, Niedzwiecki S, Pascher A et al. Long-term outcome of ATG vs. basiliximab induction. Eur J Clin Invest 2011; 41: 971-978.
19. Irish WD, McCollum DA, Tesi RJ et al. Nomogram for predicting the likelihood of delayed graft function in adult cadaveric renal transplant recipients. J Am Soc Nephrol 2003; 14: 2967-2974.
20. Irish WD, Ilsley JN, Schnitzler MA et al. A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation. Am J Transplant 2010; 10: 2279-2286.
21. Jeldres C, Cardinal H, Duclos A et al. Prediction of delayed graft function after renal transplantation. Can Urol Assoc J 2009; 3: 377-382.
22. Irwin RJ, Irwin TC. A principled approach to setting optimal diagnostic thresholds: where ROC and indifference curves meet. Eur J Intern Med 2011; 22: 230-234.
23. Noel C, Abramowicz D, Durand D et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20: 1385-1392.
24. Mikhalski D, Wissing KM, Ghisdal L et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 2008; 85: S3-S9.
25. Moore J, Ramakrishna S, Tan K et al. Identification of the optimal donor quality scoring system and measure of early renal function in kidney transplantation. Transplantation 2009; 87: 578-586.
26. Rodrigo E, Minambres E, Ruiz JC et al. Prediction of delayed graft function by means of a novel web-based calculator: A single-center experience. Am J Transplant 2012; 12: 240-244.
27. Tiong HY, Goldfarb DA, Kattan MW et al. Nomograms for predicting graft function and survival in living donor kidney transplantation based on the UNOS registry. J Urol 2009; 181: 1248-1255.
28. Foucher Y, Combescure C, Ashton-Chess J et al. Prognostic markers: data misinterpretation often leads to overoptimistic conclusions. Am J Transplant 2012; 12: 1060-1061.
29. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006; 355: 2615-2617.
30. Quiroga I, McShane P, Koo DD et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006; 21: 1689-1696.
31. Mourad G, Morelon E, Noel C et al. The role of Thymoglobulin induction in kidney transplantation: An update. Clin Transplant 2012; 26: E450-E464.
32. Boros P, Bromberg JS. New cellular and molecular immune pathways in ischemia/reperfusion injury. Am J Transplant 2006; 6: 652-658.
33. Huang Y, Rabb H, Womer KL. Ischemia-reperfusion and immediate T cell responses. Cell Immunol 2007; 248: 4-11.
34. Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant 2011; 11: 2279-2296.
35. Kamar N, Garrigue V, Karras A et al. Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: A randomized, multicenter study. Am J Transplant 2006; 6: 1042-1048.
36. Abou-Ayache R, Buchler M, Lepogamp P et al. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. Nephrol Dial Transplant 2008; 23: 2024-2032.
37. Ciancio G, Burke GW, Gaynor JJ et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immunemonitoring. Transplantation 2005; 80: 457-465.
38. Lebranchu Y, Bridoux F, Buchler M et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56.
39. Woo YM, Craig AM, King BB et al. Biocompatible membranes do not promote graft recovery following cadaveric renal transplantation. Clin Nephrol 2002; 57: 38-44.
40. Neumayer HH, Kunzendorf U, Schreiber M. Protective effects of calcium antagonists in human renal transplantation. Kidney Int Suppl 1992; 36: S87-S93.
41. Moers C, Smits JM, Maathuis MH et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009; 360: 7-19.
42. Patel SJ, Duhart BT Jr., Krauss AG et al. Risk factors and consequences of delayed graft function in deceased donor renal transplant patients receiving antithymocyte globulin induction. Transplantation 2008; 86: 313-320.
43. Abbott KC, Glanton CW, Agodoa LY. Body mass index and enrollment on the renal transplant waiting list in the United States. J Nephrol 2003; 16: 40-48.
44. Friedman AN, Miskulin DC, Rosenberg IH et al. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 2003; 41: 480-487.
45. Weissenbacher A, Jara M, Ulmer H et al. Recipient and donor body mass index as important risk factors for delayed kidney graft function. Transplantation 2012; 93: 524-529.
46. Okamoto Y, Christen T, Shimizu K et al. Adiponectin inhibits allograft rejection in murine cardiac transplantation. Transplantation 2009; 88: 879-883.
47. Vgontzas AN, Bixler EO, Papanicolaou DA et al. Chronic systemic inflammation in overweight and obese adults. JAMA 2000; 283: 2235 author reply 2236.
48. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159: 702-706.
49. R Development Core Team. R: A Language and Environment for Statistical Computing Vienna, Austria, 2010.